Envveno Medical Corp (NVNO) — DEF 14A Filings
All DEF 14A filings from Envveno Medical Corp. Browse 2 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (2)
-
NVNO Awaits FDA VenoValve Appeal Decision, Eyes New Regulatory Path
— Oct 30, 2025 Risk: high
enVVeno Medical Corp (NVNO) is actively appealing a 'not-approvable' decision from the U.S. Food and Drug Administration (FDA) regarding its VenoValve device, w -
enVVeno Medical Corp Files Definitive Proxy Statement
— Nov 19, 2024 Risk: low
enVVeno Medical Corp (formerly Hancock Jaffe Laboratories, Inc.) filed a Definitive Proxy Statement (DEF 14A) on November 19, 2024, for its fiscal year ending D
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX